Inhibitory effects of N,N'-diphenyl-p-phenylenediamine on the early stage of the enhanced hepatocarcinogenesis caused by coadministration of ethionine and a choline-deficient L-amino acid-defined diet in rats.
Effects of N,N'-diphenyl-p-phenylenediamine (DPPD), an antioxidant, on liver carcinogenesis caused by a choline-deficient L-amino acid-defined (CDAA) diet containing ethionine were studied in Fischer 344 rats. Male animals, 6 weeks old, were fed a CDAA diet, a choline-supplemented L-amino acid-defined (CSAA) diet or a CDAA diet containing 0.05% ethionine with or without 0.2% DPPD. Histological changes and lesions positive for gamma-glutamyltransferase (GGT) were analyzed 12 weeks after the beginning of the experiment. The levels of 8-hydroxyguanine (8-OHGua) in DNA and 2-thiobarbituric acid-reacting substances (TBARS) were measured as the parameters for cellular oxidative damage after 4 and 11 days of treatment. Expression of c-myc and c-Ha-ras was also investigated in relation to cell proliferation after 2, 4, 8 and 11 days. Histologically, development of diffuse fatty liver observed in rats fed a CDAA diet was inhibited, while massive oval cell proliferation and cholangiofibrosis resulted from the addition of ethionine with/without DPPD. The sizes but not numbers of GGT-positive lesions seen in the liver of rats fed a CDAA diet were increased and the levels of 8-OHGua formation and TBARS generation were also increased by the ethionine supplement. Both numbers and sizes of GGT-positive lesions were decreased and the level of TBARS, but not 8-OHGua, was decreased by adding DPPD. The increased expression of c-myc and c-Ha-ras detected in the liver of rats fed a CDAA diet was further increased by addition of ethionine and again reduced by DPPD. These results indicate that an antioxidant DPPD can inhibit the early stage of enhanced hepatocarcinogenesis caused by coadministration of ethionine and a CDAA diet, by blocking cellular oxidative damage as well as c-myc and c-Ha-ras expression.
Kobayashi
E
E
Department of Oncological Pathology, Nara Medical University, Japan.
Tsujiuchi
T
T
Nakae
D
D
Mizumoto
Y
Y
Andoh
N
N
Endoh
T
T
Kitada
H
H
Tsutsumi
M
M
Denda
A
A
Konishi
Y
Y
D000596:Amino Acids / Q000008:administration & dosage* / Q000494:pharmacology; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D002796:Choline Deficiency / Q000139:chemically induced*; D003043:Cocarcinogenesis; D005001:Ethionine / Q000633:toxicity*; D006147:Guanine / Q000031:analogs & derivatives / Q000096:biosynthesis; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D010655:Phenylenediamines / Q000494:pharmacology* / Q000627:therapeutic use*; D051381:Rats; D011916:Rats, Inbred F344
D000596:Amino Acids; D000975:Antioxidants; D010655:Phenylenediamines; C024829:8-hydroxyguanine; D006147:Guanine; C004845:N,N'-diphenyl-4-phenylenediamine; D005001:Ethionine